Allspring中小型核心主动型ETF ASCE 深 沪
等待开盘 09-14 09:30:00 美东时间
34.37
+0.150
+0.44%
华盛通- 最 高34.59
- 今 开34.59
- 成交量 6.71万股
- 最 低 34.31
- 昨 收 34.22
- 总市值 1.85亿
- 52周最高 36.3096
- 市盈率 静 --
- 换手率 1.24%
- 52周最低 24.5889
- 委 比 0.00%
- 总股本 539.70万
- 历史最高 36.3096
- 量 比 1.25
- 振 幅 0.82%
- 历史最低 24.0619
- 每 手 1
- 风险率 3.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Konukoğlu Raises Controlling Stake in ASCE Gayrimenkul Yatırım Ortaklığı to 51.15%
ASCE GAYRIMENKUL YATIRIM ORTAKLIGI A.S. ( ($TR:ASGYO) ) just unveiled an announ...
09-03 15:19
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits
Amarin (AMRN) on Friday said a new analysis of its REDUCE-IT trial found that patients who remained on icosapent ethyl for at least 18 months experienced about a 30% reduction in the relative risk of ...
08-31 00:37
EU approves Gilead’s Trodelvy combination with Keytruda for first-line breast cancer
Gilead Sciences (GILD) said Monday that the European Commission has approved Trodelvy in combination with Merck’s (MRK) Keytruda as a first-line treatment for adults with PD-L1-positive, unresectable,...
08-24 19:21
ADMA Biologics Leans on ASCENIV in Earnings Call
ADMA Biologics Inc (($ADMA)) has held its Q2 earnings call. Read on for the mai...
08-21 08:24
Liquidia (LQDA) 2026年第二季度业绩电话会议：YUTREPIA销售额增长31%
Liquidia 的 2026 年第二季度业绩电话会议涵盖了 YUTREPIA 达 1.704 亿美元的销售额、31% 的季度增长、利润上升、管线支出及其 2027 年目标。
08-14 08:27
Major Shareholder Konukoglu Raises Stake in ASCE REIT
ASCE GAYRIMENKUL YATIRIM ORTAKLIGI A.S. ( ($TR:ASGYO) ) has provided an announc...
08-05 14:15
Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations
Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen In...
07-17 00:30
Amentum rises after winning NASA’S COSMOS Contract
Shares of Amentum (AMTM) rose nearly 8% premarket on Tuesday after the company said it has been awarded NASA’s Consolidated Spaceflight Mission Operations and Systems (COSMOS) contract. The award com...
06-30 20:42
Gilead's Trodelvy gains new breast cancer indications
The US FDA has approved Gilead Sciences' (GILD) Trodelvy (sacituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's (MRK) Keytruda (pembrolizumab) for triple-nega...
06-25 04:37
